Affimed narrows PhI/IIa focus; Bristol Myers pays Agenus $25M; Merck, Moderna start another PhIII cancer vaccine
11 Dec 2023
VaccineImmunotherapyDrug ApprovalClinical StudymRNA
Plus, news on Novartis’ recently-approved iptacopan and Acurx’s antibiotic.
Affimed drops some indications from PhI/IIa trial:
As the biotech reports promising mid-stage data for its innate cell engager AFM24 in non-small cell lung cancer, the company has decided to
cut off enrollment
in the other cohorts of the trial to stay focused. That includes a gastric cancer cohort and a basket cohort in pancreatic cancer, biliary tract cancer and hepatocellular carcinoma, which showed some clinical activity that was, however, unlikely to meet its bar, Affimed said. The trial was testing AFM24, which binds to EGFR and CD16A, in combination with Roche’s PD-L1 inhibitor Tecentriq in EGFR-expressing solid tumors.
— Amber Tong
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.